In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Differential platelet alpha2B-adrenergic receptors gene expression levels following coronary stent implantation: the effect of Bioabsorbable Polymer Everolimus-Eluting Synergy stents

Session Poster session 1

Speaker Maria Marketou

Event : ESC Congress 2017

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease (Chronic)
  • Session type : Poster Session

Authors : M Marketou (Heraklion,GR), A Spanaki (Heraklion,GR), F Parthenakis (Heraklion,GR), J Kontaraki (Heraklion,GR), E Zacharis (Heraklion,GR), D Lempidakis (Heraklion,GR), G Mpantouvakis (Heraklion,GR), J Konstantinou (Heraklion,GR), J Logakis (Heraklion,GR), D Vougia (Heraklion,GR), O Theodosaki (Heraklion,GR), M Vernardos (Heraklion,GR), P Vardas (Heraklion,GR)

M. Marketou1 , A. Spanaki1 , F. Parthenakis1 , J. Kontaraki1 , E. Zacharis1 , D. Lempidakis1 , G. Mpantouvakis1 , J. Konstantinou1 , J. Logakis1 , D. Vougia1 , O. Theodosaki1 , M. Vernardos1 , P. Vardas1 , 1Heraklion University Hospital - Heraklion - Greece ,

European Heart Journal ( 2017 ) 38 ( Supplement ), 185

Purpose: Alpha2B-adrenergic receptors (α2B-ARs) play a pivotal role in platelet aggregation and their blockade exerts a profound antiaggregatory effect. In this report, we evaluated alpha2B–adrenergic receptors (α2B–ARs) gene expression levels in platelets from patients with stable coronary artery disease (CAD) undergoing coronary stent implantation.

Methods: Fifty nine patients with stable CAD (39 males, aged 68±16 years) who were under dual antiplatelet therapy with clopidogrel 75 mg and acetylsalicylic acid 100 mg and 20 healthy individuals (37 males, aged 69±8 years) were included. The patients underwent single vessel elective percutaneous coronary intervention and were randomized to one of three groups, for bare metal stents (BMS) or everolimus-eluting stents (EES) (n=19) or Bioabsorbable Polymer Everolimus-Eluting Synergy stents (Boston Scientific) implantation (n=22). Blood samples were obtained before, 24hours, 48 hours, and 1 month after stent implantation from which platelets were isolated. The α2B-ARs gene expression in platelets was examined by real time PCR.

Results: Patients with BMS showed a significantly increased gene expression of the α2B-ARs in platelets in 1 month following stent implantation (p=0.04) while EES group revealed an increase at 48 hours (p=0.05) and returned to baseline values in 1 month (Table 1). In contrast, α2B-ARs gene expression levels in Synergy group were significantly decreased at 1 month follow up (p=0.045).

Conclusions: In contrast to other types of stents, Synergy stents showed a decrease in platelets α2B-ARs gene expression levels after implantation. Possibly, this type of stent offers a favorable effect in the prevention of stent thrombosis in CAD patients.

Table 1. Serial changes of platelets α2B-ARs gene expression levels after stent implantation
Baseline24 hours48 hours1 month
BMS (n=18)3.01±3.855.41±9.025.86±7.737.18±7.78*
EES (n=19)3.65±3.565.66±5.411.15±15*5.4±6.33
Synergy stents (n=22).4.06±4.863.53±3.583.06±2.452.083±1.58*
*p<0.005 compared to baseline.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are